Table 2.
Overall survival (OS) and progression-free survival (PFS)
| Group | Median (mo) | Survival rate (%) |
||||
|---|---|---|---|---|---|---|
| 1-Year | 2-Year | 3-Year | 4-Year | 5-Year | ||
| OS | ||||||
| GIII all | 48.4 | 84.8 | 64.9 | 55.6 | 50.7 | 45.3 |
| AAw | 21.5 | 74.1 | 64.0 | 46.6 | 28.3 | 14.4 |
| AAm | n.r. | 69.3 | 55.4 | 55.4 | 55.4 | 55.4 |
| AOmc | n.r. | 96.3 | 85.9 | 85.9 | 85.9 | 85.9 |
| PFS | ||||||
| GIII all | 31.8 | 76.7 | 58.7 | 49.2 | 43.1 | 41.8 |
| AAw | 16.4 | 80.6 | 64.5 | 45.7 | 25.8 | 9.0 |
| AAm | n.r. | 88.9 | 83.0 | 83.0 | 62.2 | 62.2 |
| AOmc | 130.0 | 96.4 | 92.4 | 82.6 | 82.6 | 82.6 |
GIII, grade III glioma; AAw, anaplastic astrocytoma, IDH-wildtype; AAm, anaplastic astrocytoma, IDH-mutant; n.r., not reached; AOmc, anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted.